Targeted Therapies in the Treatment of Sarcomas
- PMID: 30143942
- DOI: 10.1007/s11523-018-0583-0
Targeted Therapies in the Treatment of Sarcomas
Abstract
About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
